BioLineRx (BLRX) Shares Outstanding (Diluted Average) (2023 - 2025)

BioLineRx (BLRX) has 3 years of Shares Outstanding (Diluted Average) data on file, last reported at $2.5 billion in Q4 2025.

• In Q4 2025, Shares Outstanding (Diluted Average) rose 105.76% year-over-year to $2.5 billion; the TTM figure through Dec 2025 stood at $2.5 billion (up 105.76% YoY), while the FY2025 annual figure was $2.5 billion, up 105.76% from the prior year.
• Shares Outstanding (Diluted Average) improved to $2.5 billion in Q4 2025, from $1.2 billion in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $2.5 billion in Q4 2025 and bottomed at $963.4 million in Q4 2023.
• A 3-year average of $1.5 billion and a median of $1.2 billion in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) increased 24.37% — and 2025, when it surged 105.76%.
• Year by year, Shares Outstanding (Diluted Average) stood at $963.4 million in 2023, then climbed by 24.37% to $1.2 billion in 2024, then jumped by 105.76% to $2.5 billion in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $2.5 billion (Q4 2025), $1.2 billion (Q4 2024), and $963.4 million (Q4 2023), per Business Quant data.

Peer Comparison